A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103)

Interventions

• Biological
  Sacituzumab tirumotecan

  IV Infusion

• Biological
  Bevacizumab

  IV Infusion

• Drug
  H1 receptor antagonist

  Rescue medication taken per approved product label before sacituzumab tirumotecan

• Drug
  H2 receptor antagonist

  Rescue medication taken per approved product label before sacituzumab tirumotecan

• Drug
  Acetaminophen (or equivalent)

  Rescue medication taken per approved product label before sacituzumab tirumotecan

• Drug
  Dexamethasone (or equivalent)

  Rescue medication taken per approved product label before sacituzumab tirumotecan

• Drug
  Steroid mouthwash (dexamethasone or equivalent)

  Rescue medication taken orally 2-4 times daily

Locations (196)